Baandrup, L;
Ostrup Rasmussen, J;
Klokker, L;
Austin, S;
Bjornshave, T;
Fuglsang Bliksted, V;
Fink-Jensen, A;
Hedegaard Fohlmann, A;
Peter Hansen, J;
Kristine Nielsen, M;
Sandsten, K. E;
Schultz, V;
Voss-Knude, S;
Nordentoft, M.
BACKGROUND AND AIM: The Danish Health and Medicines Authority assembled a group of experts to develop a national clinical guideline for patients with schizophrenia and complex mental health needs. Within this context, ten explicit review questions were formulated, covering several identified key issues. ...
The overall objective of the guidelines is to provide public health approach guidance on evidencebased practices for testing, treating and managing LTBI in individuals with the highest risk of progression to active disease. The guidelines are expected to provide the basis and rationale for the developmen...
Antitubercular Agents/administration & dosage,
Latent Tuberculosis/drug therapy,
Latent Tuberculosis/prevention & control,
Vulnerable Populations,
Treatment Outcome,
Medication Adherence,
Rifampin/administration & dosage,
Isoniazid/administration & dosage,
Drug Therapy, Combination,
Latent Tuberculosis/diagnosis
Steiner, T;
Al-Shahi Salman, R;
Beer, R;
Christensen, H;
Cordonnier, C;
Csiba, L;
Forsting, M;
Harnof, S;
Klijn, CJ;
Krieger, D;
Mendelow, AD;
Molina, C;
Montaner, J;
Overgaard, K;
Petersson, J;
Roine, RO;
Schmutzhard, E;
Schwerdtfeger, K;
Stapf, C;
Tatlisumak, T;
Thomas, BM;
Toni, D;
Unterberg, A;
Wagner, M.
"BACKGROUND:
Intracerebral hemorrhage (ICH) accounted for 9% to 27% of all strokes worldwide in the last decade, with high early case fatality and poor functional outcome. In view of recent randomized controlled trials (RCTs) of the management of ICH, the European Stroke Organisation (ESO) has updated it...
Zuberbier, T;
Aberer, W;
Asero, R;
Bindslev-Jensen, C;
Brzoza, Z;
Canonica, GW;
Church, MK;
Ensina, LF;
Giménez-Arnau, A;
Godse, K;
Gonçalo, M;
Grattan, C;
Hebert, J;
Hide, M;
Kaplan, A;
Kapp, A;
Abdul, Latiff, AH;
Mathelier-Fusade, P;
Metz, M;
Saini, SS;
Sánchez-Borges, M;
Schmid-Grendelmeier, P;
Simons, FE;
Staubach, P;
Sussman, G;
Toubi, E;
Vena, GA;
Wedi, B;
Zhu, XJ;
Nast, A;
Maurer, M.
This methods report describes the process of guideline development in detail. It is the result of a systematic literature review using the 'Grading of Recommendations Assessment, Development and Evaluation' (GRADE) methodology and a structured consensus conference held on 28 and 29 November 2012, in Berl...
"AIM:
Non-radiographic axial spondyloarthritis (nr-axSpA) is axial inflammatory arthritis where plain radiographic damage is not evident. An unknown proportion of these patients will progress to ankylosing spondylitis (AS). The increasing recognition of nr-axSpA has been greatly assisted by the widesprea...
The aim of this guidance is to provide the interim principles that should guide the use of delamanid in conjunction with WHO-recommended MDR-TB treatment. It also specifies the essential treatment and management conditions for use of this drug, in particular the patient's eligibility criteria and safety ...
Cost-Benefit Analysis,
Tuberculosis, Multidrug-Resistant/drug therapy,
Drug Therapy, Combination,
Nitroimidazoles/therapeutic use,
Treatment Outcome,
Antitubercular Agents/therapeutic use,
Tuberculosis, Pulmonary/drug therapy,
Clinical Trials as Topic,
Nitroimidazoles/economics,
Antitubercular Agents/economics
WHO estimates that up to half a million new cases of multidrug-resistant tuberculosis (MDR-TB) occur worldwide, each year. Current treatment regimens for MDR-TB present many challenges: treatment lasts 20 months or more, requiring daily administration of drugs that are more toxic, less effective, and far...
